CROI

As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchINFECTIOUS DISEASES. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has ...

The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.

Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

For more than 40 years, Rebecca Denison has lived with HIV and advocated for women affected by the virus. A longtime activist and founder of WORLD, she has witnessed the epidemic’s evolution. In this interview, she reflects on scientific progress, ongoing challenges, and why the fight against HIV is far from over.

In this interview, Skye Opsteen, touchINFECTIOUS DISEASES Future Leader 2025, shares the moments that reinforced her dedication to her specialty, the invaluable lessons from mentors and advice for aspiring infectious disease researchers. She highlights the power of curiosity, mentorship and trusting one’s instincts in navigating the evolving landscape of infectious disease medicine.

The Conference on Retroviruses and Opportunistic Infections (CROI) is the leading global meeting for HIV research, bringing together over 4,000 experts from around the world. It serves as a platform for researchers to translate laboratory and clinical discoveries into meaningful advancements ...

As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.

HIV vaccine development harnesses breakthroughs in structure-based antigen design, sequencing, and single-cell analysis to create potent vaccines. Prof. Barney Graham, Professor of Medicine, Microbiology, Chemistry and Immunology, Morehouse School of Medicine in Atlanta, Georgia, USA explores advances reported at CROI 2024, emphasizing advances in targeting antibody lineages and augmenting CD8+ T cell responses, and highlighting sustaining funding models for HIV research and it's imperativeness for addressing broader public health issues.

HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.